Funabashi, Japan

Yo Kishikawa

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Nissan Chemical Industries Limited. Active years: 2014.


% Patents Active = 100.0

 

Average Co-Inventor Count = 6.0

ph-index = 1


Company Filing History:


Years Active: 2014

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Yo Kishikawa

Introduction

Yo Kishikawa is a notable inventor based in Funabashi, Japan. He has made significant contributions to the field of therapeutic agents, particularly in the treatment of multiple myeloma. His work exemplifies the intersection of chemistry and medicine, showcasing the potential of innovative compounds in healthcare.

Latest Patents

Kishikawa holds a patent for "Pyrazole compounds having therapeutic effect on multiple myeloma." This patent presents novel therapeutic agents for myeloma, specifically a therapeutic agent that contains a pyrazole compound represented by a specific formula. His research aims to provide effective treatment options for patients suffering from this challenging condition.

Career Highlights

Kishikawa is associated with Nissan Chemical Industries Limited, where he has been able to apply his expertise in developing innovative chemical solutions. His work at the company has allowed him to focus on creating compounds that can have a significant impact on medical treatments.

Collaborations

Throughout his career, Kishikawa has collaborated with esteemed colleagues such as Taito Nishino and Katsuaki Miyaji. These collaborations have fostered a productive environment for innovation and have contributed to the advancement of therapeutic agents in the pharmaceutical industry.

Conclusion

Yo Kishikawa's contributions to the field of therapeutic agents highlight the importance of innovation in medicine. His work not only addresses critical health issues but also paves the way for future advancements in treatment options.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…